GEN Exclusives

More »

GEN News Highlights

More »
Aug 7, 2007

Beta-Amyloid Also Involved in Glaucoma

  • A group of scientists report that they have evidence implicating beta-amyloid in glaucoma. The research carried out at the UCL Institute of Ophthalmology also showed that drugs being tested for Alzheimer's disease, which target this protein, may be used to treat glaucoma.

    The research team developed a new technology for visualising nerve cell damage in the retina, known as detection of apoptosing retinal cells. They demonstrated that the protein beta-amyloid also leads to nerve cell death in the retina.

    Using animal models, the scientists also found that drugs that work to prevent the build up of the beta-amyloid in Alzheimer’s brains can be used to treat glaucoma. One such drug, Bapineuzumab, is already being used in clinical trials to treat Alzheimer's patients by pharmaceutical companies Elan and Wyeth in the US. In the study, the scientists combined it with two other novel Alzheimer's treatments and found that the effects on glaucoma were even stronger.

    The research was published August 6 in the Proceedings of the National Academy of Sciences.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »